Impact of Desensitization on Antiviral Immunity in HLA-Sensitized Kidney Transplant Recipients

Table 5

CMV and EBV viremia in sero(+) non-DES patients who received valganciclovir (VGCV-LD) versus acyclovir prophylaxis (ACV-anti-IL-2R).

Patients	Number of patients (%)
	w/CMV-PCR > 30 copies/PCR
CMV sero(+) non-DES
VGCV-LD ()	31 (17.6)
ACV-anti-IL-2R ()	26 (14.9)
VGCV-LD-ATZ ()	7 (28.0)
VGCV-LD-ATG ()	24 (15.9)
	w/EBV-PCR > 30 copies/PCR
EBV sero(+) non-DES
VGCV-LD ()	22 (11.0)
ACV-anti-IL-2R ()	6 (2.8)
VGCV-LD-ATZ ()	2 (5.1)
VGCV-LD-ATG ()	20 (12.4)

VGCV: valganciclovir; ACV: acyclovir.
LD: lymphocyte depletion; anti-IL-2R: anti-IL-2 receptor.
ATZ: alemtuzumab; ATG: anti-thymocyte globulin.
⁢ versus VGCV-LD by Fisher’s exact test.